PDCD1 and neoplasm: Such upregulation may indicate heightened immune cell activity within the tumor microenvironment and imply that these patients potentially exhibit a more favorable response to immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 therapies [37].